EA201370121A1 - Визуализирующие средства - Google Patents

Визуализирующие средства

Info

Publication number
EA201370121A1
EA201370121A1 EA201370121A EA201370121A EA201370121A1 EA 201370121 A1 EA201370121 A1 EA 201370121A1 EA 201370121 A EA201370121 A EA 201370121A EA 201370121 A EA201370121 A EA 201370121A EA 201370121 A1 EA201370121 A1 EA 201370121A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hce
cells
imaging agent
intracellular
disubstituted
Prior art date
Application number
EA201370121A
Other languages
English (en)
Inventor
Майкл Хью Чарлтон
Давид Фестус Чарльз Моффат
Стивен Джон Давис
Алан Хастингс Друммонд
Original Assignee
Хрома Терапетикс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хрома Терапетикс Лтд. filed Critical Хрома Терапетикс Лтд.
Publication of EA201370121A1 publication Critical patent/EA201370121A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Визуализирующее средство для клеток, которое производит внутриклеточный визуализирующий сигнал, пропорциональный количеству hCE-1 в клетках независимо от количества hCE-2 и/или hCE-3 в клетках, при этом указанное визуализирующее средство является ковалентным конъюгатом (а) визуализирующего средства и (b) сложного эфира моно- или дизамещенной α-аминокислоты, в котором (а) непосредственно связан с (b), или (а) опосредованно связан с (b) линкерным радикалом, и в котором указанное непосредственное или опосредованное связывание осуществляется через аминогруппу (b), и в котором аминогруппа не является непосредственно связанной с карбонильной группой, и в котором указанная часть сложного эфира моно- или дизамещенной α-аминокислоты является селективно гидролизируемой до соответствующей части карбоновой кислоты ферментом внутриклеточной карбоксилэстеразы hCE-1 в отличие от внутриклеточных ферментов hCE-2 или hCE-3.
EA201370121A 2010-12-17 2011-12-16 Визуализирующие средства EA201370121A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1021467.4A GB201021467D0 (en) 2010-12-17 2010-12-17 Imaging agents
PCT/GB2011/001729 WO2012080705A1 (en) 2010-12-17 2011-12-16 Imaging agents

Publications (1)

Publication Number Publication Date
EA201370121A1 true EA201370121A1 (ru) 2013-08-30

Family

ID=43598579

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201370121A EA201370121A1 (ru) 2010-12-17 2011-12-16 Визуализирующие средства

Country Status (14)

Country Link
US (1) US20140010762A1 (ru)
EP (1) EP2651454A1 (ru)
JP (1) JP2013545795A (ru)
KR (1) KR20140004676A (ru)
CN (1) CN103391789A (ru)
AU (1) AU2011343017A1 (ru)
BR (1) BR112013014586A2 (ru)
CA (1) CA2821856A1 (ru)
EA (1) EA201370121A1 (ru)
GB (1) GB201021467D0 (ru)
MX (1) MX2013006393A (ru)
SG (1) SG191121A1 (ru)
WO (1) WO2012080705A1 (ru)
ZA (1) ZA201304156B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
SG10201708166SA (en) 2012-10-17 2017-11-29 Macrophage Pharma Ltd Tert-Butyl N-[2-{4-[6-Amino-5-(2,4-Difluorobenzoyl)-2-Oxopyridin-1(2H)-yl]-3,5-Difluorophenyl}Ethyl]-L-Alaninate Or A Salt, Hydrate Or Solvate Thereof
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960700986A (ko) * 1994-01-12 1996-02-24 네나드 토모브-그리소고노 리간드 및 이들의 금속착체(ligands and metal complexes thereof)
US20030082106A1 (en) * 2000-01-22 2003-05-01 Aleksandr Nivorozhkin Magnetic resonance imaging using contrast agents bioactivated by enzymatic cleavage
US20030170176A1 (en) * 2001-03-14 2003-09-11 Mcgill University Individualization of therapy with antipsychotics
WO2005086612A2 (en) * 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
US7091211B2 (en) * 2003-07-31 2006-08-15 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity

Also Published As

Publication number Publication date
WO2012080705A1 (en) 2012-06-21
JP2013545795A (ja) 2013-12-26
MX2013006393A (es) 2013-09-13
GB201021467D0 (en) 2011-02-02
ZA201304156B (en) 2014-02-26
SG191121A1 (en) 2013-07-31
US20140010762A1 (en) 2014-01-09
AU2011343017A1 (en) 2013-07-18
KR20140004676A (ko) 2014-01-13
BR112013014586A2 (pt) 2019-02-19
CN103391789A (zh) 2013-11-13
EP2651454A1 (en) 2013-10-23
CA2821856A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
MX345608B (es) Materiales y metodos para conjugar un derivado de acido graso soluble en agua a una proteina.
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
MA34519B1 (fr) Anticorps anti-fap et procédés d'utilisation
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
IN2015DN00194A (ru)
MY158663A (en) Fermentation broth formulations
MY160552A (en) Low protein infant formula with increased essential amino acids
TR201900067T4 (tr) Ketiyapinin yağ asidi konjugatları, bunların yapılmasına ve kullanılmasına yönelik proses.
WO2010091049A3 (en) Diagnosis and treatment of cancer
UY34343A (es) Proteinas de unión al antígeno cd27l
TR201903336T4 (tr) Fermantasyonda gelişmiş karbon yakalama.
BR112012013782A2 (pt) "antagonistas de pcsk9"
MX336607B (es) Formas novedosas de dosificacion de liberacion modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa.
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
GT201200322A (es) Derivados de carbamato de hexafluoroisoprofilo, su preparacion y su aplicacion en terapeutica
EA201291357A1 (ru) Способы лечения с применением ингибиторов tlr7 и/или tlr9
IN2014DN09922A (ru)
IN2014DN10639A (ru)
WO2007056511A3 (en) Metal-binding therapeutic peptides
EA201170294A1 (ru) Способы лечения реперфузионных повреждений
MA34541B1 (fr) Compositions d'anticorps et procédés d'utilisation
EA201370121A1 (ru) Визуализирующие средства
FR2968561B1 (fr) Utilisation d'un anticorps dirige contre une proteine membranaire
EA201391144A1 (ru) Композиции для обработки волос